Showing 4,701 - 4,720 results of 4,835 for search '"biomedical"', query time: 0.07s Refine Results
  1. 4701
  2. 4702
  3. 4703
  4. 4704
  5. 4705
  6. 4706
  7. 4707
  8. 4708
  9. 4709
  10. 4710
  11. 4711
  12. 4712
  13. 4713
  14. 4714
  15. 4715
  16. 4716
  17. 4717
  18. 4718
  19. 4719

    Utility of 131I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models by Liu Y, Wang X, Zhang N, He S, Zhang J, Xu X, Song S

    Published 2025-01-01
    “…Yi Liu,1– 4,* Xiao Wang,1– 3,5,* Ni Zhang,1– 4,* Simin He,1– 4 Jianping Zhang,1– 4 Xiaoping Xu,1– 4 Shaoli Song1– 4 1Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, People’s Republic of China; 3Center for Biomedical Imaging, Fudan University, Shanghai, 200032, People’s Republic of China; 4Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, 200032, People’s Republic of China; 5State Key Laboratory of Vaccines for Infectious Diseases, Xiang an Biomedicine Laboratory & Center for Molecular Imaging and Translational Medicine, School of Public Health, Shenzhen Research Institute of Xiamen University, Xiamen University, Xiamen, 361102, People’s Republic of China*These authors contributed equally to this workCorrespondence: Shaoli Song; Xiaoping Xu, Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, People’s Republic of China, Email shaoli-song@163.com; xxp0012@ustc.eduPurpose: None of the antibody-drug conjugates (ADCs) targeting Claudin 18.2 (CLDN18.2) have received approval from regulatory authorities due to their limited clinical benefits. …”
    Get full text
    Article
  20. 4720